Chargement en cours...

Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial)

BACKGROUND: The POP Trial was a phase 1, open-label, rising-dose, randomised study that explored the safety and tolerability of calmangafodipir (superoxide dismutase mimetic) co-treatment with n-acetylcysteine (NAC) for paracetamol overdose. METHODS: Patients were recruited at the Royal Infirmary of...

Description complète

Enregistré dans:

Détails bibliographiques
Publié dans:	EBioMedicine
Auteurs principaux:	Morrison, Emma E., Oatey, Katherine, Gallagher, Bernadette, Grahamslaw, Julia, O'Brien, Rachel, Black, Polly, Oosthuyzen, Wilna, Lee, Robert J., Weir, Christopher J., Henriksen, Dennis, Dear, James W.
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2019
Sujets:	Research paper
Accès en ligne:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6710902/ https://ncbi.nlm.nih.gov/pubmed/31311721 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.07.013
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial)

Documents similaires

Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial)